Overview

Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

Status:
Active, not recruiting
Trial end date:
2035-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Kite, A Gilead Company
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate